Domain Therapeutics to Present Data on its GPCR Lead Programs at AACR Annual Meeting 2025
- Presentation of Phase I clinical results from DT-9081, an EP4 receptor antagonist, and preclinical data on DT-7012, a Treg depleting anti-CCR8 antibody
- Preclinical findings highlight immuno-oncology breakthrough properties for its PAR2 biased negative allosteric modulator program
- Posters present the potential of GPCRs to modulate the tumor microenvironment and enhance anti-tumor immunity
Strasbourg, France – Montreal, Canada – Boston, United States, April 1, 2025: Domain Therapeutics (“Domain” or “the Company”), the GPCR experts harnessing deep receptor biology to develop breakthrough treatments for patients, today announces that it will be presenting new preclinical and clinical data on its key oncology programs – DT-7012, and DT-9081, alongside preclinical findings on its PAR2 biased negative allosteric modulator (NAM) program – at the upcoming American Association for Cancer Research (AACR) Annual Meeting 2025, taking place in Chicago, US from 25-30 April 2025.
